




Background

Amura Therapeutics Limited is a drug discovery business specialising in the development of inhibitors of CAC1 cysteine peptidases. Cysteine peptidases are involved in several commercial and therapeutically important diseases such as **osteoporosis, bone metastasis, osteoarthritis, rheumatoid arthritis, multiple sclerosis, atherosclerosis, chronic pain** and **malaria**. Amura's compounds are derived from the proprietary **AMcore™** scaffold, which provides a turnkey solution for inhibitor design against cysteine peptidases of the CAC1 family. Amura has discovered novel chemical entities (NCE's) that are readily synthesised and exhibit excellent *in vitro* activity, primary DMPK stability, rodent and non-human primate oral pharmacokinetics, safety pharmacology, functional cell-based activity and efficacy in *in vivo* disease related animal models. Amura intends to out-license its programmes for clinical development.



Cathepsin K Inhibitors

Amura's **AMcore™** derived inhibitors have proven efficacious in a variety of industry gold standard animal models targeting blockbuster therapeutic indications. All compounds tested are via oral administration and key highlights include:-

Osteoporosis

- In a non-human primate study, multiple compounds significantly reduced serum bone markers (sCTXI and sNTx); improving upon the profile of competitor compounds that have entered the clinic. The pharmacodynamic effect is maintained for many hours upon single oral dose.
- In an ovariectomized rat model of osteoporosis, multiple compounds demonstrated a dose dependant and significant decrease in serum bone markers (sCTXI) As a result, turnover index (sCTXI/osteocalcin) was significantly decreased by all six test compounds.
- Compounds show excellent pharmacokinetic profiles, safety pharmacology and toxicity profile.

Bone metastasis

- In a human breast cancer cell-induced mouse model of bone metastasis, compound demonstrated a reduction in lesion size and total tumour burden associated with metastasis compared to the control group.
- Compounds show excellent pharmacokinetic profiles, safety pharmacology and toxicity profile.

Osteoarthritis

- In a rat surgical menisectomy model of osteoarthritis, compound showed significant beneficial effects on tibial cartilage degeneration and total joint score compared to the control group.
- Additionally, compound demonstrated a significant decrease in synovial fluid collagen markers (CTxI and CTxII) in a rat surgical menisectomy model.
- Compounds show excellent pharmacokinetic profiles, safety pharmacology and toxicity profile.

SENIOR MANAGEMENT

Dr. David Brown
Chairman

Dr Martin Quibell
Chief Scientific Officer

Dr Daniel Roach
General Manager

Amura Holdings Ltd.
Minerva Building
Babraham Research Campus
Babraham
Cambridgeshire
CB22 3AT
United Kingdom

☎ +44(0)1223 839797
☎ +44(0)1223 839898
✉ amura@amura.co.uk
🌐 www.amura.co.uk



Cathepsin S Inhibitors

Amura's **AMcore™** derived inhibitors have proven efficacious in a variety of industry gold standard animal models targeting blockbuster therapeutic indications. All compounds tested are via oral administration and key highlights include:-

Rheumatoid arthritis


- In a collagen-induced arthritis animal model, compound demonstrated a marked reduction in collagen-specific antibodies.
- Additionally, a significant decrease in joint swelling score was observed, along with a significant improvement in joint histopathology.
- Compounds show excellent pharmacokinetic profiles, safety pharmacology and toxicity profile.

Chronic neuropathic pain

- In a rat sciatic nerve ligation model, multiple compounds demonstrated a rapid and marked inhibition of mechanical hyperalgesia.
- Inhibition was dose-dependant and fully reversible.
- Compounds show excellent pharmacokinetic profiles, safety pharmacology and toxicity profile.

AMcore™ intellectual property

The key proprietary **AMcore™** bicyclic scaffolds are:



	AU	BR	CA	CN	EU	HK	IN	ID	IL	JP	KR	MX	NZ	NO	PH	RU	SA	SG	UA	US
WO02057270	G	U	U	G	G	G	G	G	G	U	U	G	G	P	P	G	G	G	G	G
WO04007501	P	U	P	U	G	P	U		P	U	P		G		P		G	G		G

G Granted
 U Under examination
 P Pending

	2001	2002	2003	2004	2005	2006	2007	2008	Exp. date
WO02057248	Cysteine protease inhibitor								01-2021
WO02057270	Cysteine protease inhibitor								01-2021
WO02057246	Cysteine protease inhibitor								01-2021
WO02057249	Cysteine protease inhibitor								01-2021
WO04007501	Cysteine protease inhibitor								07-2022
WO07017698							AMcore™ Process1		08-2025
WO07023281							Mimetics		08-2025
WO0807132							AMcore™ Process2		07-2026
WO0807109							Selection		07-2026
WO0807103							Selection		07-2026
WO0807130							Selection		07-2026
WO0807114							Selection		07-2026
WO0807127							Selection		07-2026
WO0807107							Selection		07-2026
WO0807112							Selection		07-2026
GB0800338.6									01-2028
GB0804701.1									03-2028
GB0804792.9									03-2028
GB0809776.8									05-2028

The granted patents protect the use of **AMcore™** derived 5,5-bicyclic ketones as inhibitors of CAC1 cysteine peptidases to provide new medicines for diseases such as **osteoporosis, bone metastasis, osteoarthritis, rheumatoid arthritis, chronic pain and malaria.**

Amura intends to out-license/partner its programmes for clinical development.



AMURA INVESTORS

Avlar BioVentures

☎ +44(0)1954 211 515
 ☎ +44(0)1223 211 516
 ✉ avlar@avlar.com
 🌐 www.avlar.com

Noble Group

☎ +44(0)20 7763 2200
 ☎ +44(0)20 7763 2399
 ✉ noble@noblegp.com
 🌐 www.noblegp.com

LICENSING OPPORTUNITIES

Dr. David Brown

☎ +44(0)1223 839797
 ☎ +44(0)1223 839898
 ✉ david.brown@amura.co.uk
 🌐 www.amura.co.uk